Kura Oncology, Inc. (KURA)

Kura Oncology topped consensus on both the top and bottom line in the second fiscal quarter of 2026 (period ended June 30, 2026, reported August 12, 2026), with EPS of -$0.77 topping the -$0.88 estimate by $0.11 and revenue of $20.9 million topping the $20.2 million estimate (+3.5%). Revenue rose 37% to roughly $20.9 million, up from about $15.3 million a year ago, as the company continued to generate revenue alongside its oncology pipeline work in programs such as KOMZIFTI and other targeted candidates. Gross profit came in at around $20.6 million, with gross margin near 99%, while operating income was -about $73.0 million. Net income was negative roughly $68.3 million, down 3% from about -$66.1 million a year ago, and the -$0.77 EPS compared with -$0.75 a year ago. For the next period, consensus calls for EPS of -$0.84 on revenue of $23.8 million.